Navigation Links
Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
Date:1/27/2009

of reovirus within liver metastases after intravenous administration of REOLYSIN(R) by examination of the resected tumour. Secondary objectives include assessing the anti-tumour activity and safety profile of REOLYSIN(R), and monitoring the humoral and cellular immune response to REOLYSIN(R).

Eligible patients include those with histologically proven colorectal cancer, planned for potentially curative surgical resection of liver metastases. Up to 20 patients will receive one cycle of treatment in this trial, with approximately 10 in each of the early and late virus groups.

The University of Leeds is covering all costs of the trial, while Oncolytics will provide REOLYSIN(R).

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. translational study for patients with metastatic colorectal cancer with liver metastases, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R)
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
2. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
3. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
4. Researchers at Axial Biotech Develop a DNA Test for Scoliosis
5. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
6. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
7. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
8. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
9. Pulmo BioTech Inc. Completes Bio-Distribution Studies
10. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Pharma Major ... in ZAO "Biocom" in Russia subject ... the Russian pharmaceutical market which recorded RUB 765 billion in ... markets in the world in 2014 (IMS Health). For over ... expected to continue with this trend, projecting Russia ...
(Date:7/2/2015)... -- Konica Minolta, Inc. (Konica Minolta) ( Tokyo ... Technologica Ltda., an X-ray system equipment manufacturer based in ... Brazilian healthcare sales company, Konica Minolta Healthcare do ... Brazil market investment and growth With ... significant healthcare technical advancements and efficiencies are required. Aging ...
(Date:7/2/2015)... , South Korea, July 2, 2015 ALPINION MEDICAL ... new E-CUBE Series ultrasound system. Developed to enhance user ... areas, the E-CUBE 15 EX produces superb image quality. ... performance in women,s health, general imaging, and shared service ... The latest in the renowned E-CUBE Series, the E-CUBE ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3
... PLYMOUTH MEETING, Pa., Nov. 8, 2011   Health technology ... are the most serious device-related risks, and how can ... nonprofit that researches the best approaches to improving patient ... hospital,s patient safety initiatives with the release of its ...
... Alexza Pharmaceuticals, Inc. (Nasdaq:  ALXA) today announced that ... and Mental Health Congress, being held November 7 - ... Agitation with Inhaled Loxapine (AZ-004): Responder Analyses in Patients ... by Dr. James V. Cassella, Alexza,s Senior Vice President ...
Cached Medicine Technology:ECRI Institute Announces its Top 10 Health Technology Hazards for 2012 2ECRI Institute Announces its Top 10 Health Technology Hazards for 2012 3ECRI Institute Announces its Top 10 Health Technology Hazards for 2012 4Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference 2Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference 3Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference 4Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference 5
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report ... number of obese Americans outnumber merely overweight Americans, Samir Becic emphatically declared a war ... to American society right now," Becic said. "We must understand the magnitude of this ...
(Date:7/2/2015)... ... ... Many Fourth of July celebrations will include fireworks this summer, so it’s ... some tips to promote the proper use of fireworks. , According to the U.S. ... with fireworks-related injuries in the month surrounding the Fourth of July. Amica is sharing ...
(Date:7/2/2015)... ... ... “ LIFX ” was featured on NewsWatch as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... , According to the U.S. Department of Energy, it’s very important to use energy-efficient ...
(Date:7/2/2015)... ... , ... Global leader and compression innovator, SIGVARIS North America, is ... For style that’s quick on its feet, men will love this fun new way ... everywhere because a simple change in socks can dramatically help improve overall leg health ...
(Date:7/2/2015)... Diego, CA (PRWEB) , ... July 02, 2015 , ... ... and a passion for social fitness. Built to function as a lifestyle community, Active ... giving them the opportunity to network, meet, and participate in discussions or group events. ...
Breaking Medicine News(10 mins):Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... used in clinical trials on a path ... to finally cure ... upon us,are you struggling to find the perfect gift for a ... those afflicted with diabetes simply,by participating in the Spring Point Project ...
... HealthSouth,Corporation (NYSE: HLS ) today announced it ... Department of Justice on behalf of the,Office of ... and Human,Services (HHS) to resolve issues associated with ... settlement amount of $14.2,million was previously disclosed in ...
... Three Years After ... ... a continued benefit of ARIMIDEX when compared to tamoxifen in,treating postmenopausal ... (ARIMIDEX, Tamoxifen, Alone or in,Combination) trial, reported today at the 2007 ...
... says 10-milligram dose works, but advisers urge study of ... A decongestant in many of the most popular over-the-counter ... health experts ruled Friday. But they also urged that ... to the U.S. Food and Drug Administration had heard ...
... lifestyle changes, study finds , FRIDAY, Dec. 14 (HealthDay ... habits for employees, a new U.S. study finds. ... work lives have healthier lifestyles. Individuals who perceive an ... some positive lifestyle changes," lead author Joseph G. Grzywacz, ...
... Dec. 14 (HealthDay News) -- A decongestant in some ... at its current dosage, a panel of U.S. health ... the U.S. Food and Drug Administration had heard day-long ... phenylephrine really provide nasal congestion relief. , The medicines, ...
Cached Medicine News:Health News:Sponsor a Spring Point Project Pig for the Holidays 2Health News:Sponsor a Spring Point Project Pig for the Holidays 3Health News:HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government 2Health News:Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer 2Health News:Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer 3Health News:Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer 4Health News:Decongestant in OTC Cold Remedies Effective: FDA Panel 2Health News:Decongestant in OTC Cold Remedies Effective: FDA Panel 3Health News:Workplace Flexibility Can Boost Healthy Behaviors 2Health News:FDA Panel Finds OTC Cold Remedies Effective 2Health News:FDA Panel Finds OTC Cold Remedies Effective 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: